CDK7 and mature T-cell and NK-cell non-Hodgkin lymphoma: To validate the inhibition of CDK7 as therapeutic target in PTCL cell lines, we used THZ1-R, a THZ1 analog with no significant inhibitory activity of CDK7 in cells9.